169 related articles for article (PubMed ID: 27334363)
1. Identification of Ebsulfur Analogues with Broad-Spectrum Antifungal Activity.
Ngo HX; Shrestha SK; Garneau-Tsodikova S
ChemMedChem; 2016 Jul; 11(14):1507-16. PubMed ID: 27334363
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
5. Novel fluconazole derivatives with promising antifungal activity.
Thamban Chandrika N; Shrestha SK; Ngo HX; Howard KC; Garneau-Tsodikova S
Bioorg Med Chem; 2018 Feb; 26(3):573-580. PubMed ID: 29279242
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
7. In vitro assessment of the growth and plasma membrane H
Orie NN; Warren AR; Basaric J; Lau-Cam C; Piętka-Ottlik M; Młochowski J; Billack B
J Biochem Mol Toxicol; 2017 Jun; 31(6):. PubMed ID: 28151580
[TBL] [Abstract][Full Text] [Related]
8. Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells.
Thangamani S; Eldesouky HE; Mohammad H; Pascuzzi PE; Avramova L; Hazbun TR; Seleem MN
Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt A):3002-3010. PubMed ID: 27712973
[TBL] [Abstract][Full Text] [Related]
9. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
10. Oxadiazolylthiazoles as novel and selective antifungal agents.
Hagras M; Salama EA; Sayed AM; Abutaleb NS; Kotb A; Seleem MN; Mayhoub AS
Eur J Med Chem; 2020 Mar; 189():112046. PubMed ID: 31962263
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibitory action of ebselen on fluconazole-resistant Candida albicans: role of the plasma membrane H+-ATPase.
Billack B; Santoro M; Lau-Cam C
Microb Drug Resist; 2009 Jun; 15(2):77-83. PubMed ID: 19432523
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
Chandrika NT; Shrestha SK; Ngo HX; Garneau-Tsodikova S
Bioorg Med Chem; 2016 Aug; 24(16):3680-6. PubMed ID: 27301676
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.
Skóra M; Bulanda M; Jagielski T
Antimicrob Agents Chemother; 2015 Sep; 59(9):5827-9. PubMed ID: 26100698
[TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Pfaller MA; Castanheira M; Messer SA; Jones RN
Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
[TBL] [Abstract][Full Text] [Related]
15. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Dagi HT; Findik D; Senkeles C; Arslan U
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
[TBL] [Abstract][Full Text] [Related]
16. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
17. A combination approach to treating fungal infections.
Shrestha SK; Fosso MY; Garneau-Tsodikova S
Sci Rep; 2015 Nov; 5():17070. PubMed ID: 26594050
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.
Badali H; Khodavaisy S; Fakhim H; de Hoog GS; Meis JF; Chowdhary A
Antimicrob Agents Chemother; 2015 Dec; 59(12):7818-22. PubMed ID: 26369976
[TBL] [Abstract][Full Text] [Related]
19. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
20. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
